Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular Multi-Arm, Phase 1, Adaptive Design Study to Evaluate the Safety and Tolerability of RXC004, Alone and in Combination With Anti-cancer Treatments, in Patients With Advanced Malignancies

NCT03447470 is registered in ClinicalTrials.gov with Redx Pharma Ltd as lead sponsor.

NCT NCT03447470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03447470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular Multi-Arm, Phase 1, Adaptive Design Study to Evaluate the Safety and Tolerability of RXC004, Alone and in Combination With Anti-cancer Treatments, in Patients With Advanced Malignancies
Lead sponsor
Redx Pharma Ltd
Phase
Phase 1
Overall status
Completed
Start date
March 18, 2019
Completion date
September 29, 2023
Enrollment
46 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, solid tumor